DDInter948 DDInter1477
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.
Pirfenidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Pirfenidone {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Pirfenidone {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Pirfenidone may lead to a major life threatening interaction when taken with Amiodarone
Pirfenidone may lead to a major life threatening interaction when taken with Rucaparib